KarXT xanomeline/trospium chloride Updated Nov 7
KarXT is already approved and launching in China, so the next stock-moving events for Zai Lab around this drug are commercial milestones: NRDL (national reimbursement) negotiation outcomes, quarterly sales growth trends, and any label expansion for Alzheimer's psychosis or bipolar mania that Zai Lab might pursue in China. The next major binary catalyst for Zai Lab overall is the November 30, 2026 PDUFA date for povetacicept in IgAN, not KarXT.
- First-in-class mechanism: KarXT is the first schizophrenia drug with a novel mechanism in over 50 years, addressing a massive unmet need across 8 million+ patients in China alone.
- Approved and launching: NMPA approval secured in December 2025 and commercial launch in China began June 2026, with early launch trends described as encouraging by management.
- Strong institutional accumulation: Multiple tracked managers (FMR LLC, Goldman Sachs, Woodline Partners) doubled or initiated positions in Zai Lab during Q2 2026, signaling confidence in the commercial opportunity.
- No near-term binary catalyst: With both US and China approvals secured, there is no upcoming PDUFA or pivotal readout for KarXT to drive a sharp re-rating for Zai Lab.
- Commercial execution risk: KarXT is a new entrant in China's schizophrenia market; NRDL reimbursement inclusion is not guaranteed and pricing negotiations could pressure margins.
- Insider selling: CFO Chen Yajing and director Lis William sold shares in August 2026 (some under 10b5-1 plans), which may signal limited near-term upside conviction from insiders.